This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
U.S. News & World Report
Lung cancer is the deadliest form of cancer for a few reasons. First, it's the second most commonly diagnosed form of cancer behind only skin cancer. The American Cancer Society reports that about 14 percent of all new cancers are diagnosed in the lungs and estimates that in the U.S. in 2018, 234,030 new cases of lung cancer will be diagnosed and about 154,050 people will die of the disease. That accounts for more than a quarter of all cancer deaths in the U.S.
READ MORE
|
Promoted by
|
|
|
|
 |
ScienceDaily
Fitness trackers can be valuable tools for assessing the quality of life and daily functioning of cancer patients during treatment, a new study has found. The trackers, also known as wearable activity monitors, include commercial devices worn on the wrist that log a wearer's step counts, stairs climbed, calories, heart rate and sleep.
READ MORE
Scientific American
Many forms of childhood cancers have gone from being a death sentence to a curable disease. Thanks to advances in treatments, the overall survival rate for childhood cancers has increased from 10 percent a few decades ago to nearly 90 percent today. This means that by the year 2020, an estimated half a million survivors of childhood cancer will be living in the U.S. With more children surviving, though, it has become increasingly clear that cancer and the subsequent treatments, such as chemo or radiation therapy, can have long-term negative effects that extend beyond physical problems such as hair loss, pain and physical disability.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our
 ihcDirect® product list.
|
|
The San Antonio Express
Elephants have 100 times as many cells as humans, but they seldom get cancer. This is surprising, because cancer is a result of cell division gone wrong, and the more cells an organism has, the higher the chances that some will mutate into tumors. Also, because elephants live so long — between 60 and 70 years — their cells have more opportunities to mutate. The counterintuitive observation that cancer risk does not always correlate with a species' size or longevity is known as Peto's Paradox, named after British epidemiologist Richard Peto, who first noted the phenomenon in 1977.
READ MORE
Oncology Nurse Advisor
Cancer incidence rates have decreased among men but remained stable among women, while cancer death rates are decreasing for both men and women, according to a report published in the July 1 issue of Cancer.
Kathleen A. Cronin, PhD, MPH., from the National Cancer Institute in Bethesda, Maryland, and colleagues examined trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast.
Donate today.
|
|
Technology Networks
Scientists have unveiled clues about a mysterious molecule called Yin Yang1 — and revealed it may fuel tumor growth in breast cancer.
The findings, by a group of international scientists led by Imperial College London, may open avenues for new treatments and help us understand why some tumors become resistant to chemotherapy.
Crucially, the findings also reveal how tumors can change their "appearance" to evade cancer treatments, using a system called epigenetics.
READ MORE
Technology Networks
A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.
READ MORE
OncLive
Although PD-L1 has been coined an “imperfect biomarker” and tumor mutational burden (TMB) is still investigational in many ways, the adoption of immunotherapy agents into frontline treatment continues for patients with non–small cell lung cancer (NSCLC), despite the inability to accurately select patients, said John A. Kosteva, M.D.
READ MORE
Medical Xpress
Two current drugs used to treat psychosis and depression showed anti-cancer activity in mice by blocking the movement of cholesterol within drug-resistant cancer cells, according to Penn State Cancer Institute researchers. Certain types of cancers need high levels of cholesterol to survive. In this study, 42 drugs, anti-psychotics or anti-depressants, were compared against a compound called leelamine that has been shown to stop the movement of cholesterol in cancer cells.
READ MORE
| ACS CANCER PROGRAMS UPDATES |
ACS
Endometrial cancer is the most common gynecologic malignancy in the U.S. and is second only to cervical cancer worldwide. Endometrioid adenocarcinoma is the most common subtype and portends a positive prognostic factor when low- or intermediate-grade and compared with other histopathologies. Important risk factors for endometrial cancer include age, predisposing genetic syndromes and prolonged exposure to estrogen in the absence of progestins. Obesity is a modifiable risk factor for endometrial cancer and is becoming increasingly important in counseling patients in the setting of the international obesity epidemic. Treatment typically includes surgery, with radiation or chemotherapy reserved for high-risk lesions. In counseling patients with endometrial cancer, it is important that care be coordinated by a gynecologic oncologist.
READ MORE
ACS
Enter the Cancer Programs Annual Conference featured session
Leadership: How to Take People Where They Don't Necessarily Want to be but Ought to Be
9:30-10:30 a.m., Thursday, Sept. 6
The Cancer Programs are very excited to have Aaron Bleznak, MBA, FACS speak at the upcoming annual conference this September. Dr. Bleznak's presentation "Leadership: How to Take People Where They Don't Necessarily Want to Go but Ought to Be" is based on his sold out session "The Science of Leadership and Becoming an Influencer" at the Quality and Safety Conference in July. During his presentation, he will review the science and best practices involving leadership and exerting influence.
The session is based on the science of leadership through elements of neuropsychology. The lecture will help strengthen your ability to influence and manage key elements of CoC and NAPBC accreditation.
By attending this it will provide you with unique tools to understand your leadership strengths and weaknesses enhance your knowledge of how to influence others, and guide you to recognize your best skills to educate others to come across as an ever stronger and effective leader to your cancer committee.
If you are serious about building your leadership skills and bringing forward effective change in your organization you don't want to miss the 2018 Cancer Programs Annual Conference!
Register now to ensure your spot and secure early-bird pricing.
READ MORE
Clinical Research Program
As mentioned in prior communications, the 2018 DCIS Special Study is opening July 16. We invite you to visit the 2018 Special Study on DCIS SharePoint site, which will house all materials you will need to participate in the study. We have created a universal login for this site; please note it is case sensitive:
Login: DCISStudy
Password: study2018.
All registrars and co-registrars will be able to access and download materials via the SharePoint site.
READ MORE
ACS
The National Cancer Database (NCDB) is pleased to announce that the Participant User File (PUF) application will be open through Aug. 6. The NCDB will accept applications for site-specific files, which include cases diagnosed between 2004 and 2015. The 2016 PUF, which will include 2004-2016 diagnosis years, will be available for request during the next application period, January 2019.
The NCDB PUF is a Health Insurance Portability and Accountability Act (HIPAA) compliant data file containing cases submitted to the Commission on Cancer's (CoC) NCDB and complies with the terms of the Business Associate Agreement between the American College of Surgeons and cancer programs accredited by the CoC; i.e., no patients or facilities can be identified. The PUF is designed to provide investigators at CoC-accredited cancer programs with a data resource they can use to review and advance the quality of care delivered to cancer patients through analyses of cases reported to the NCDB.
For more information, review the PUF Website.
Questions regarding the NCDB PUFs or the RFA process for a PUF may be directed to NCDB technical staff at NCDB_PUF@facs.org.
American College of Surgeons - NAPRC
The National Accreditation Program for Rectal Cancer (NAPRC) is now accepting applications. The NAPRC was developed to ensure that rectal cancer patients receive appropriate care following a multidisciplinary approach. Programs will be evaluated on the standards and metrics outlined in The National Accreditation Program for Rectal Cancer Standards Manual 2017 (revised October 2017).
READ MORE
ACS
The American College of Surgeons (ACS) 2018 Cancer Programs Annual Conference: Learn. Interact. Transform provides cutting-edge solutions to help you deliver high-quality, patient-centered, multidisciplinary care to patients with cancer. Through a combination of plenaries, breakout sessions and networking opportunities you will leave this conference reinvigorated and ready to overcome the challenges facing you as a cancer care provider.
Detailed information, as well as conference agenda, can be found on the Cancer Programs Annual Conference website.
Register now to take advantage of the early-bird registration fee and SAVE.
READ MORE
ACS
The AJCC Cancer Staging Manual is the gold standard to help the cancer patient management team determine the correct stage for patients, allowing for the most appropriate care plan.
The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neoplastic diseases. Proper classification and staging of cancer is essential for the physician to assign proper treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.
This corrected third printing includes the following features:
- Revised breast cancer staging system
- Revised histology codes in each chapter
- Corrected errata posted on www.cancerstaging.org through Feb. 2.
Special 25 percent discount! Expires Oct. 30.
Click here for the Springer Order Form.
READ MORE
| IMPORTANT DATES AND DEADLINES |
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
